Real-World Glycemic Outcomes of a tubeless Automated Insulin Delivery System: A Single-Center Observational Study in Italy

Silvia Angelino¹Maria Ida Maiorino^1,2*Michela Petrizzo³Nicole Di Martino³Paola Caruso³Carla Carbone³Alessandro Pontillo³Antonietta Maio³Miriam Longo^1,4Lorenzo Scappaticcio¹Giuseppe Bellastella¹Katherine Esposito¹

• ¹Università degli Studi della Campania Luigi Vanvitelli Dipartimenti di Scienze Mediche e Chirurgiche Avanzate, Naples, Italy
• ²University of Campania Luigi Vanvitelli, Caserta, Italy
• ³Azienda Ospedaliera Universitaria Luigi Vanvitelli, Naples, Italy
• ⁴Link Campus University, Department of Life Science, Health, and Health Professions, Rome, Italy

Background - The objective of this study is to describe the short-term change observed in CGM-related measures and relevant clinical variables in individuals with type 1 diabetes transitioning to Omnipod 5 insulin treatment within a real-world setting. Methods – The study involved adults with type 1 diabetes treated with Omnipod 5, whose data were collected over a 14-days observation period prior to (Time 0) and following the (Time 1) initiation of the patch pump use. Results – A total of 20 adults with well-controlled glycemia and no diabetes-related complications were included in the study. From baseline to follow-up, Time in Range (TIR) significantly increased from 57.3% to 67.3% (P<0.001). Concurrently, there were significant decreases in Time Above Range (TAR) Level 1 (mean difference, -4.7 ± 6.1%, P=0.003) and Level 2 (-4.2 ± 6.1%, P=0.018), as well as in Time Below Range (TBR) Level 1 (-1.0 ± 1.1%, P<001), TBR Level 2 (-0.4 ± 0.5%, P=0.015), and Glycemia Risk Index (-13.8 ± 15.1 P<0.001). Importantly, no significant changes in insulin doses were observed during the study period. Conclusions – Omnipod 5 initiation allowed participants to improve CGM-related metrics and the quality of glucose control in the short-term, without the increasing the need for insulin without increasing the need for insulin.